Skip to main content

Notice for sotatercept (Merck Sharp & Dohme (Australia) Pty Ltd)

Active ingredients
Date of review outcome
Lapse date
Priority review
For the treatment of pulmonary arterial hypertension (PAH) in adult patients on standard of care with WHO Functional Class (FC) II to III, to improve exercise capacity, provide clinical improvement, improve WHO FC and delay disease progression, including to reduce the risk of death and hospitalisation for PAH
Therapeutic area

Help us improve the Therapeutic Goods Administration site